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Abstract
Bevirimat (1, BVM) is an anti-HIV agent that blocks HIV-1 replication by interfering with HIV-1
Gag-SP1 processing at a late stage of viral maturation. However, clinical trials of 1 have revealed
a high baseline drug resistance that is attributed to naturally-occurring polymorphisms in HIV-1
Gag. To overcome the drug resistance, 28 new derivatives of 1 were synthesized and tested against
compound 1-resistant (BVM-R) HIV-1 variants. Among them, compound 6 exhibited much
improved activity against several HIV-1 strains carrying BVM-R polymorphisms. Compound 6
was at least 20-fold more potent than 1 against the replication of NL4-3/V370A, which carries the
most prevalent clinical BVM-R polymorphism in HIV-1 Gag-SP1. Thus, compound 6 merits
further development as a potential anti-AIDS clinical trial candidate.
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INTRODUCTION
After three decades of battle against Acquired Immunodeficiency Syndrome (AIDS) and its
causative agent human immunodeficiency virus type 1 (HIV-1), HIV-1 infection remains
one of the leading causes of infectious diseases worldwide with more than 30 million people
currently living with HIV/AIDS.1 Although current anti-retroviral therapy (ART) has
drastically improved the clinical outcome of AIDS, it fails to eradicate HIV-1 from
patients.2-4 Thus, long-term treatment is required to suppress HIV-1 replication in infected
patients. The emergence of drug-resistant HIV strains and the side effects/toxicities
associated with long-term drug treatment present additional obstacles for the clinical
management of HIV-1 infection.5,6 Therefore, identifying new drug candidates with novel
mechanisms of action is vital to advancing AIDS therapy.
Bevirimat (1, BVM), also known as PA-457, DSB, and MPC-4326, is a first-in-class HIV-1
maturation inhibitor that interferes with the CA-SP1 cleavage step of Gag processing,
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resulting in the accumulation of p25 and immature viral cores.7-10 Clinical trials indicated
that 1 caused a significant and clinically relevant reduction of the viral load in both ART-
experienced and naive patients.11,12 However, the clinical trials also revealed a high baseline
drug resistance to 1. A significant fraction (40–50%) of treated patients had pre-existing
resistant viruses that had significantly reduced sensitivity to 1.13-15 This BVM-resistance
was linked to naturally-occurring HIV polymorphisms in the SP1 region of HIV-1 Gag.
Polymorphisms within three amino acids, Gln-Val-Thr (Q-V-T), at Gag positions 369–371
of the SP1, such as 370A instead of V or deleted V or T, were shown to be associated with
the BVM-resistance (Table 1). A polymorphism of 362I in the CA region of Gag was also
reported to confer resistance to compound 1.16 Analysis of SP1 sequences indicated that
370A is the most prevalent polymorphism among HIV-1 isolates from subtype B and C
viruses.17 The high baseline drug resistance due to the existing polymorphisms poses serious
limitations to the clinical potential and further development of compound 1.
It has been shown that 1 does not bind to monomeric Gag, but rather binds to an immature
Gag to interfere with the CA-SP1 cleavage. It was suggested that 1 associated with an alpha
helical structure of SP1 of immature viral particles.18,19 SP1 with BVM-R polymorphisms
could disrupt the binding of 1, leading to a loss of sensitivity to the compound. The goal of
this study was to modify the structure of 1 to overcome the resistance. Our prior studies
indicated that attachment of a side chain at the C28 position of 1 resulted in improved
activity. For example compound 30 (N-[3β-O-(3′,3′-dimethylsuccinyl)lup-20(29)-en-28-
oyl]-5-piperazinepentanoic acid), with a C28 piperazinepentanoic acid side chain on the
compound 1 molecule, exhibited a greater than 10-fold increase in anti-HIV-1 maturation
activity.20 In spite of its increased activity against wild type virus, 30 was not effective
against BVM-R viruses. Nevertheless, its improved anti-HIV-1 activity against the NL4-3
strain suggested that C28 modifications could impact drug-target interaction. Thus, the
rationale of this study was that compound 1 analogs with optimized C28 side chains might
improve drug-target interaction and overcome the resistance to compound 1.
RESULTS
New analogs were synthesized with compound 1 as the scaffold and various spacer/R’
groups at the C28 position (Figure 1). Compounds 2–18 contain an ω-aminoalkanoic acid
spacer [H2N-(CH2)n-COOH], where n ranged from 6–9. Compounds 19–29 have a 1,ω-
diaminoalkane [H2N-(CH2)n-NH2] spacer, where n was 7–9.
As shown in Scheme 1, compounds 2–18 were synthesized by first coupling the C28
carboxylic acid of 3-O-acetate-BA with benzyl ω-aminoalkanoates (Table 2). The coupling
reaction was then followed by alkaline hydrolysis to form intermediates 2a–4a and 18a,
which are known compounds that have been previously reported for their activities against
HIV-1 and HIV-2 viruses.21-23 Further modifications at the C28 terminal carboxylic acid of
the above intermediates with the corresponding amino acid ester in the presence of EDC,
HOBt, and NMM resulted in 2b–4b and 6b–18b. Treatment of 2b–4b and 6b–18b with 2,2-
dimethylsuccinic anhydride and DMAP in pyridine at 140 °C for 2 h using microwave
radiation yielded the final compounds 2–4 and 6–18. Compound 5 was obtained by alkaline
hydrolysis of 4.
Compounds 19–29 were synthesized by coupling the diaminoalkane with the C28 carboxylic
acid of 3-O-acetate-BA to form amine intermediates 19a, 21a and 26a.21,23 Further coupling
of the above amine intermediate with a corresponding N-protected amino acid, followed by
alkaline hydrolysis of the esters at C3 resulted in compounds 19b–29b. Esterification of
19b–29b at the C3 hydroxyl formed the end products 19–29 (Scheme 2; Table 3).
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Activity of Compound 1 Derivatives against BVM-R HIV-1 Variant V370A
To evaluate the effectiveness of the newly synthesized compound 1 analogs against BVM-R
HIV-1 strains, a panel of NL4-3 mutants carrying BVM-R polymorphisms was
constructed.23 The NL4-3 sequences of the polymorphic site in SP1 and its flanking region
are shown in Table 1 along with the sequences of BVM-R mutants. The synthesized
compounds were tested initially against both the wild type HIV-1 NL4-3 and NL4-3/V370A,
a variant that carries the most prevalent BVM-R polymorphism with an Ala at position 370
in the SP1 region.
As expected, 1 potently inhibited wild type NL4-3 with an IC50 of 0.076 μM, but was
ineffective at up to 6.8 μM against the BVM-R variant NL4-3/V370A. Most of the newly
synthesized analogs (2–29) were more potent than 1 against wild type NL4-3 (Tables 2 and
3). Twenty-four of the new compounds had IC50 values in the range of 0.01–0.05 μM, six in
the range of 0.07–0.18 μM, and three were over 0.2 μM or inactive. In contrast to 1, most of
the new C28 modified analogs exhibited inhibitory activity against the BVM-R NL4-3/
V370A variant with IC50 values less than 3 μM. Ten of the tested compounds exhibited
significant potency against this variant with IC50 values ranging from 0.16 to 0.47 μM.
Among them, compounds 5, 6, 14, 15, 20, 21, 24, and 29 also had improved potency (IC50 ≤
0.05 μM) against wild type NL4-3 compared with 1. Compound 6 with a C28 methyl
nonanoyl-glutaminate side chain, exhibited the best anti-HIV potency against both wild type
virus and the BVM-R NL4-3/V370A variant with IC50 values of 0.01 and 0.16 μM,
respectively. The improved activity of these compounds over 1 was not accompanied with
increased cytotoxicity, as their CC50 values were comparable to that of 1 (Tables 2 and 3).
Compound 6 Inhibited Multiple NL4-3 Variants Carrying BVM-R Polymorphisms
Due to its superior anti-HIV activity, compound 6 was tested against three more BVM-R
variants that carry BVM-R polymorphisms (Table 1). While these viruses were not sensitive
to 1 (Table 4), all four BVM-R variants with V370Δ, V370A, V362I, and T371Δ
polymorphisms were sensitive to 6. The IC50 values of 6 against these resistant variants
ranged from 0.016 to 0.32 μM compared with 0.008 μM against wild type NL4-3 (Table 4).
The rank order of sensitivity of the BVM-R variants to 6 was NL4-3/V362I > NL4-3/T371Δ
> NL4-3/V370A > NL4-3/V370Δ.
Inhibition of CA-SP1 Processing of BVM-R HIV-1 Variant by Compound 6
As a maturation inhibitor, compound 1 causes the accumulation of p25 by interfering with
the HIV-1 Gag CA-SP1 cleavage.7-10 To determine whether anti-HIV-1 maturation was
indeed responsible for the observed anti-HIV activity, 6 was tested in a standard anti-
maturation assay that measures p25 accumulation.10,18 NL4-3 and the BVM-R variant
NL4-3/V370A were produced by 293T cells in the presence of 1 or 6. The Gag CA-SP1
(p25) protein and its processed product p24 were detected with Western blot analysis. As
expected, 1 interfered with the cleavage of Gag CA-SP1 in wild type NL4-3 as shown by
p25 accumulation, but did not inhibit the cleavage of Gag CA-SP1 in the drug resistant
variant NL4-3/V370A under the same experimental conditions (Figure 2a). These results
agree with the anti-viral assay results of 1. On the other hand, treatment of the BVM-R
NL4-3/V370A virus with 6 resulted in accumulation of CA-SP1 (p25), the signature event
of inhibition of HIV-1 maturation. The accumulation of p25 was even more pronounced
when the BVM-R NL4-3/V362I virus was produced in the presence of 6 (Figure 2b). This
was consistent with the anti-viral results that NL4-3/V362I was most sensitive to 6 among
the BVM-R mutants. These data indicated that 6 is a potent maturation inhibitor effective
against both wild type and BVM-R mutants.
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Compound 6 was Inactive against HIV-1 Entry
We and others have previously shown that betulinic acid (BA) derivatives with C28
modified side chains can block HIV-1 replication at the viral entry step.25,26 To determine
whether 6 also inhibits HIV-1 entry, 6 was tested in a fusion assay that was previously
established for studying HIV-1 entry inhibitors.23 A43D (31), a BA derivative with a C28
modified side chain but without the C3 side chain of 1, was used as a positive control for
inhibition of HIV-1 entry.24 The results indicated that 1 and 6 do not inhibit HIV-1 entry,
while 31 strongly inhibited the HIV-1 NL4-3 Env-mediated cell-cell fusion with an IC50 of
0.042 μM (Figure 3). These results suggested that 6 inhibited the maturation of BVM-R
viruses without affecting viral entry.
DISCUSSION and CONCLUSIONS
This study demonstrates that structural optimization can result in analogs of 1 that are
effective against BVM-R viruses. Compound 6 was at least 20-fold more potent than 1
against four BVM-R viruses. The improved potency against BVM-R viruses is due to the
ability of the modified compounds to inhibit maturation of the viruses. Most of the
derivatives of 1 that had increased potency against the resistant variants were also more
potent against BVM-R viruses. However, improved potency against the sensitive virus alone
was not sufficient to overcome resistance to compound 1. For example, compound 30 was
more potent than other tested compounds against the compound 1-sensitive virus NL4-3, but
it was ineffective against BVM-R variants. It appears that the improved activity against
BVM-R viruses is associated with the BA scaffold modified at the C28 position with a long
aliphatic side chain containing a spacer with 7–9 methylenes and terminated with a suitable
amide group. This structural feature is shared by 5, 6, 14, 15, 20, 21, 24, and 29, which
displayed significant improvements in potency against BVM-R viruses.
The BVM-R variants were not equally sensitive to 6. The differential sensitivity is probably
due to the variation in the amino acid residues at the drug resistant polymorphism site. In
summary, it is possible to overcome resistance to 1, since 6 showed markedly improved
activity against the variant with the most prevalent BVM-R polymorphism, 370A in SP1 of
HIV-1 Gag. However, optimal structural requirement(s) for inhibition of each BVM-R




All solvents and reagents were used as received from Sigma-Aldrich or other commercial
sources. Positive or negative HR-FABMS were recorded on a Shimadzu LCMS-IT-TOF or a
Joel SX-102 mass spectrometer. 1H and 13C NMR spectra were measured on a Varian
Mercury 300 MHz spectrometer. Samples were dissolved in CDCl3 with TMS as an internal
standard unless specified. Silica gel chromatography was carried out on an ISCO
CombiFlash Rf flash chromatograph system with a pre-packed Redi Sep Rf Si gel column
(Teledyne ISCO), and MeOH/DCM (0–10% gradient) as mobile phase. Compounds were
analyzed and purified (as needed) by using a Varian ProStar HPLC system with a PDA
detector and Agilent Zorbax C18 columns (5 μM particle size, 4.6 × 250 mm and 9.4 × 250
mm for analytical and semi preparative scales, respectively). The mobile phase was
composed of solution A (5% acetonitrile in water with 0.045% trifluoroacetic acid) and
solution B (water/methanol/acetonitrile = 5:10:85 with 0.045% trifluoroacetic acid). A linear
gradient of 80% to 100% of solution B with a flow rate at 1 mL/min or 4 mL/min was used
in HPLC experiments. The compounds were analyzed with the UV absorption displayed at
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220 nm and recorded at a range from 200 to 250 nm. All tested compounds have purity of
95% or above determined by HPLC analysis.
General Procedure for Preparation of Compounds 2–4, 6–18 (Scheme 1)
The intermediates 2b–4b and 6b–18b were synthesized using previously described
methods.21-23 Under enclosed conditions flushed with N2, oxalyl chloride (2 mL, 20 mmol)
was added to a stirring solution of betulinic acid-3-O-acetate (500 mg, 1 mmol) in DCM
(anhydrous, 6 mL). After being stirred for 1 h at rt, the reaction mixture was concentrated
and benzyl 9-amino nonanoate (315 mg, 1.2 mmol) in DCM (anhydrous, 6 mL) and Et3N
(0.85 mL, 6 mmol) were added. After being stirred overnight at rt, the reaction mixture was
concentrated and chromatographed on Si-gel to yield 472 mg (63% yield) of intermediate.
To a solution of this intermediate in THF (4 mL) and MeOH (4 mL), NaOH (2 mL, 4N) was
added drop-wise. After being stirred overnight at rt, the reaction mixture was neutralized
with HCl (1N). The precipitate was collected, washed with water, and dried in vacuum to
give hydrolyzed intermediate 18a (303 mg, 80% yield).
A solution of 18a (45 mg, 0.07 mmol) in DCM (3 mL) was added to EDC-HCl (17 mg, 0.09
mmol), HOBt (11 mg, 0.09 mmol), NMM (17 mL, 0.15 mmol), and methyl glutaminate (33
mg, 0.21 mmol). After being stirred overnight at rt, the reaction mixture was diluted with
DCM (40 mL), and then washed with water and brine. The organic layer was dried with
Na2SO4 and concentrated in vacuum. The residue was chromatographed on Si-gel and
reverse phase HPLC to yield compound 18b (28 mg, 51% yield).
A mixture of intermediate 18b (15 mg, 0.02 mmol), 2,2-dimethylsuccinic anhydride (35 mg,
0.27 mmol), and DMAP (3 mg, 0.025 mmol) in pyridine (anhydrous, 0.5 mL) was heated to
140 °C for 2 h in a microwave oven (Biotage initiator). The mixture was then concentrated
under vacuum. The residue was chromatographed on Si-gel and reverse phase HPLC to
yield compound 18 (6 mg, 34% yield).
The above method was used to synthesize compounds 2–4 and 6–17 using different reagents
such as other alkanoates and/or amino acid derivatives instead of benzyl 9-amino nonanoate
and methyl glutaminate, respectively.
Procedure for Preparation of Compound 5
NaOH (32 mg, 0.8 mmol) was added to a solution of 4 (4 mg, 0.005 mmol) in THF (1.4
mL), H2O (0.7 mL) and MeOH (0.7 mL). After being stirred overnight at rt, the reaction
mixture was neutralized with HCl (1N). The mixture was diluted with DCM (30 mL), and
then washed with water and brine. The organic layer was dried with Na2SO4 and
concentrated in vacuum. The residue was chromatographed on reverse phase HPLC to yield
compound 5 (3 mg, yield 76%).
General Procedure for Preparation of Compounds 19–29 (Scheme 2)
Under enclosed conditions flushed with N2, oxalyl chloride (12 mmol) was added to a
stirring solution of betulinic acid-3-O-acetate (300 mg, 0.6 mmol) in DCM (anhydrous, 3
mL). After being stirredfor 1 h at rt, the reaction was concentrated to dryness and was re-
dissolved in DCM (anhydrous, 3 mL). The latter solution was added drop-wise to a stirring
solution of 1,7-diaminoheptane (470 mg, 3.6 mmol) in DCM (10 mL). After being stirred
overnight at rt, the reaction mixture was concentrated, re-dissolved in MeOH, and filtered.
The filtrate was concentrated and chromatographed on Si-gel to yield 19a (256 mg, yield
69%).
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To a stirring solution of 19a (43 mg, 0.07 mmol) in DCM (2 mL), EDC-HCl (53 mg, 0.27
mmol), HOBt (53 mg, 0.4 mmol), TEA (0.2 mmol), and Boc-glutamine (50 mg, 0.2 mmol)
were added. After being stirred overnight at rt, the reaction mixture was diluted with DCM
(40 mL), and then washed with water and brine. The organic layer was dried with Na2SO4
and concentrated in vacuum. The residue was chromatographed on Si-gel and reverse phase
HPLC to yield intermediate (46 mg, 78% yield). To the mixture of this intermediate in THF
(1 mL) and MeOH (1 mL), NaOH (0.5 mL, 4N) was added drop-wise. After being stirred
for 5 h at rt, the reaction mixture was neutralized with HCl (1N), and then extracted with
DCM. After removal of the organic solvent under vacuum, the residue was
chromatographed on Si-gel to give 19b (26 mg, 65% yield).
Using the same procedure described above to obtain 18 from 18b, 19b was further modified
at the C3 position to furnish compound 19 (9 mg, 32%).
The above method (for obtaining 19 from betulinic acid-3-O-acetate) was used to synthesize
compounds 20–29 using different reagents such as other 1,ω-diaminoalkane and/or amino
acid derivatives instead of 1,7-diaminoheptane and Boc-glutamine, respectively.
Methyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-7-
aminoheptanoyl]-L-glutaminate (2)—Yield 7 mg (22%). 1H NMR (CDCl3/Pyridine-
d5) δ 7.03 (bs, 1H, -CONH-), 6.81 and 5.68 (2bs, 1H each, -CONH2), 5.83 (bs, 1H, -
CONH-), 4.68 (s, 1H, =CH), 4.51–4.56 (m, 2H, -COCH-, =CH), 4.43 (dd, J = 4.7 Hz, J =
11.1 Hz, -CH- in 3), 3.67 (s, 3H, -OCH3), 3.04–3.24 (m, 3H, -CONH-CH2-, -CH- in 19),
2.66 and 2.55 (2d, J = 15.3 Hz, 1H each, -C(CH3)2-CH2-), 1.62 (s, 3H, -CH3 in 30), 1.29
and 1.28 (2s, 3H each, -CO-C(CH3)2), 0.89 (s, 3H, -CH3), 0.86 (s, 3H, -CH3), 0.78 (s, 3H, -
CH3), 0.73 (s, 6H, 2 × -CH3). Calcd for C49H79N3O9Na (M+Na)+: 876.5714. Found:
876.5714.
Methyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-8-
aminooctanoyl]-L-glutaminate (3)—Yield 10 mg (33%). 1H NMR δ 6.95 and 6.88
(2bs, 1H each, -CONH2), 6.64 (d, J = 7.7 Hz, 1H, -CONH-), 5.75 (t, J = 5.4 Hz, 1H, -
CONH-), 4.72 (s, 1H, =CH), 4.55–4.62 (m, 2H, -COCH-, =CH), 4.47 (dd, J = 6.5 Hz, J = 9.1
Hz, 1H, -CH- in 3), 3.77 (s, 3H, -OCH3), 3.04–3.30 (m, 3H, -CONH-CH2-, -CH- in 19),
2.69 and 2.54 (2d, J = 15.5 Hz, 1H each, -C(CH3)2-CH2-), 1.68 (s, 3H, -CH3 in 30), 1.29
and 1.27 (2s, 3H each, -CO-C(CH3)2), 0.96 (s, 3H, -CH3), 0.91 (s, 3H, -CH3), 0.82 (s, 6H, 2
× -CH3), 0.78 (s, 3H, -CH3). Calcd for C50H82N3O9 (M+H)+: 868.6046. Found: 868.6043.
Methyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-9-
aminononanoyl]-L-glycinate (4)—Yield 4 mg (34%). 1H NMR δ 6.07 (bs, 1H, -
CONH-), 5.60 (t, J = 6.0 Hz, 1H, -CONH-), 4.73 and 4.58 (2s, 1H each, =CH2), 4.48 (m,
1H, -CH- in 3), 4.05 (d, J = 5.2 Hz, 2H, -CO-CH2-NH-), 3.76 (s, 3H, -OCH3), 3.10–3.30 (m,
3H, -CONH-CH2-, -CH- in 19), 2.42–2.69 (m, 5H, -C(CH3)2-CH2-, -CO-CH2-, -CH- in 13),
1.67 (s, 3H, -CH3 in 30), 1.29 (m, 6H, -COC(CH3)2), 0.95 (s, 3H, -CH3), 0.92 (s, 3H, -CH3),
0.82 (s, 6H, 2 × -CH3), 0.80 (s, 3H, -CH3). Calcd for C48H79N2O8 (M+H)+: 811.5725.
Found: 811.5729.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-9-aminononanoyl]-
L-glycine (5)—Yield 3 mg (76%). 1H NMR (CDCl3/Pyridine-d5) δ 7.10 and 6.94 (2bs, 1H
each, 2 × -CONH-), 4.80 and 4.63 (2s, 1H each, =CH2), 4.54 (m, 1H, -CH- in 3), 4.15 (t, J =
4.3 Hz, 2H, -CO-CH2-NH-), 3.14–3.36 (m, 3H, -CONH-CH2-, -CH- in 19), 2.64–2.79 (m,
5H, -C(CH3)2-CH2-, -COCH2-, -CH- in 13), 1.70 (s, 3H, -CH3 in 30), 1.30 (m, 6H, -CO-
C(CH3)2), 0.97 (s, 6H, 2 × -CH3), 0.87 (s, 3H, -CH3), 0.82 (s, 3H, -CH3), 0.79 (s, 3H, -
CH3). Calcd for C47H76N2O8Na (M+Na)+: 819.5499. Found: 819.5470.
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aminononanoyl]-L-glutaminate (6)—Yield 15 mg (40%). 1H NMR (CDCl3/Pyridine-
d5) δ 7.03 (d, J = 7.5 Hz, 1H, -CONH-), 6.86 (bs, 1H, 1H in -CONH2), 5.85–5.89 (m, 2H, -
CONH- and 1H in -CONH2), 4.66 (s, 1H, =CH), 4.48–4.55 (m, 2H, -COCH-, =CH), 4.42
(dd, J = 4.5 Hz, J = 11.1 Hz, 1H, -CH- in 3), 3.64 (s, 3H, -OCH3), 3.05–3.24 (m, 3H, -
CONH-CH2-, -CH- in 19), 2.65 and 2.53 (2d, J = 15.1 Hz, 1H each, -C(CH3)2-CH2-), 1.61
(s, 3H, -CH3 in 30), 1.26 and 1.21 (2s, 3H each, -COC(CH3)2), 0.88 (s, 3H, -CH3), 0.85 (s,
3H, -CH3), 0.76 (s, 3H, -CH3), 0.71 (s, 6H, 2 × -CH3). 13C NMR (CDCl3/Pyridine-d5, 75
MHz) δ 179.9, 176.3, 175.1,173.8, 172.7, 171.6, 151.2, 109.5, 81.3, 55.7, 55.6, 52.5, 52.1,
50.7, 50.3, 47.0, 45.3, 42.6, 40.9, 40.7, 39.3, 38.6 × 2, 37.9, 37.2, 36.5, 34.5, 33.9, 32.0,
31.1, 30.0, 29.9, 29.6, 29.3, 29.2 × 2, 28.0, 27.1, 26.1, 25.7 × 2, 25.6, 23.8, 21.1, 19.6, 18.3,
16.7, 16.3 × 2, 14.8. Calcd for C51H84N3O9 (M+H)+: 882.6202. Found: 882.6203.
t-Butyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-9-
aminononanoyl]-L-glutaminate (7)—Yield 2 mg (17%). 1H NMR δ 7.52, 6.91, and
5.64 (3bs, 1H each, -CONH-, -CONH2), 6.23 (d, J = 7.8 Hz, 1H, -CONH-), 4.73 and 4.60
(2s, 1H each, =CH2), 4.40–4.50 (m, 2H, -CO-CH-NH-, -CH- in 3), 2.94–3.16, 3.42–3.70 (m,
3H, -CONH-CH2-, -CH- in 19), 2.79 and 2.47 (2d, J = 15.0 Hz, 1H each, -C(CH3)2-CH2-),
1.68 (s, 3H, -CH3 in 30), 1.47 (s, 9H, -C(CH3)3), 1.28 (m, 6H, -CO-C(CH3)2), 0.96 (s, 3H, -
CH3), 0.92 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.78 (s, 3H, -CH3), 0.77 (s, 3H, -CH3).
Calcd for C54H89N3O9 Na (M+Na)+: 946.6496. Found: 946.6498.
Benzyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-9-
aminononanoyl]-L-glutaminate (8)—Yield 5 mg (28%). 1H NMR δ 7.36 (bs, 5H,
ArH), 7.22 (bs, 2H, -CONH2-), 6.83 (bs, 1H, -CONH-), 6.59 (d, J = 6.9 Hz, 1H, -CONH-),
5.19 (s, 2H, -OCH2-), 4.73 (s, 1H, =CH), 4.60 (m, 2H, -CO-CH-NH-, =CH), 4.71 (m, 1H, -
CH- in 3), 3.30–3.42, 3.00–3.17 (m, 3H, -CONH-CH2-, -CH- in 19), 2.71 and 2.54 (2d, J =
15.9 Hz, 1H each, -C(CH3)2-CH2-), 1.68 (s, 3H, -CH3 in 30), 1.28 (m, 6H, -CO-C(CH3)2),
0.96 (s, 3H, -CH3), 0.90 (s, 3H, -CH3), 0.82 (s, 3H, -CH3), 0.78 (s, 6H, 2 × -CH3). Calcd for
C57H87N3O9Na (M+Na)+: 980.6340. Found: 980.6355.
Methyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-9-
aminononanoyl]-L-isoleucinate (9)—Yield 14 mg (48%). 1H NMR δ 6.18 (d, J = 8.7
Hz, 1H, -CONH-), 5.71 (bs, 1H, -CONH-), 4.72 (s, 1H, =CH), 4.59–4.67 (m, 2H, -CONH-
CH-, =CH), 4.48 (t, J = 6.0 Hz, -CH-in 3), 3.74 (s, 3H, -OCH3), 3.05–3.26 (m, 3H, -CONH-
CH2-, -CH- in 19), 2.67 and 2.56 (2d, J = 15.9 Hz, 2H, -C(CH3)2-CH2-), 2.39 (t, J = 10.2
Hz, 1H, -CH- in 13), 2.63 (t, J = 7.2 Hz, 2H, -CO-CH2-), 1.67 (s, 3H, -CH3 in 30), 1.29 (m,
6H, -CO-C(CH3)2), 0.95 (s, 3H, -CH3), 0.91 (s, 6H, 2 × -CH3), 0.89 (s, 3H, -CH3), 0.82 (s,
6H, 2 × -CH3), 0.79 (s, 3H, -CH3). Calcd for C52H86N2O8Na (M+Na)+: 889.6282. Found:
889.6294.
Methyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-9-
aminononanoyl]-L-prolinate (10)—Yield 17 mg (59%). 1H NMR δ 5.75 (bs, 1H, -
CONH-), 4.72 and 4.59 (2s, 1H each, =CH2), 4.45–4.54 (m, 2H, -CON-CH-, CH- in 3),
3.51-3.77 (m, 5H, -OCH3, -CONCH2-), 3.04–3.25 (m, 3H, -CONH-CH2-, -CH- in 19), 2.67
and 2.56 (2d, J = 16.2 Hz, 2H, -C(CH3)2-CH2-), 1.68 (s, 3H, -CH3 in 30), 1.29 (m, 6H, -CO-
C(CH3)2), 0.95 (s, 3H, -CH3), 0.91 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.79 (s, 3H, -
CH3). Calcd for C51H82N2O8Na (M+Na)+: 873.5969. Found: 873.5989.
Methyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-9-
aminononanoyl]-L-phenylalaninate (11)—Yield 18 mg (67%). 1H NMR δ 7.26–7.28
(m, 3H, ArH), 7.08 (d, 2H, J = 6.6 Hz, ArH), 5.92 (d, J = 7.2 Hz, 1H, -CONH-), 5.59 (bs,
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1H, -CONH-), 4.90 (dd, J = 6.0 Hz, J = 12.9 Hz, 1H, -CO-CH-NH-), 4.72 and 4.58 (2s, 1H
each, =CH2), 4.47 (t, J = 6.3 Hz, 1H, -CH- in 3), 3.72 (s, 3H, -OCH3), 3.67 (d, 2H, J = 6.9
Hz, -CH2-C6H6), 3.05–3.30 (m, 3H, -CONHCH2-, -CH- in 19), 2.52–2.69 (m, 2H, -
C(CH3)2-CH2-), 2.44 (t, J = 9.9 Hz, 1H, -CH- in 13), 1.67 (s, 3H, -CH3 in 30), 1.28 (m, 6H,
-CO-C(CH3)2), 0.95 (s, 3H, -CH3), 0.92 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.79 (s, 3H, -
CH3). Calcd for C55H84N2O8Na (M+Na)+: 923.6125. Found: 923.6142.
Methyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-9-
aminononanoyl]-L-valinate (12)—Yield 8 mg (45%). 1H NMR δ 6.09 (d, J = 8.4 Hz, -
CONH-), 5.67 (m, 1H, -CONH-), 4.72 (s, 1H, =CH), 4.56–4.60 (m, 2H, =CH, -CO-CH-
NH-), 4.48 (t, J = 6.9 Hz, 1H, -CH- in 3), 3.75 (s, 3H, -OCH3), 3.07–3.28 (m, 3H, -CONH-
CH2-, -CH- in 19), 2.67 and 2.56 (2d, J = 15.9 Hz, 1H each, -C(CH3)2-CH2-), 2.41 (t, J =
11.7 Hz, -CH- in 13), 2.27 (t, J = 7.5 Hz, 2H, -COCH2-), 1.68 (s, 3H, -CH3 in 30), 1.28 (m,
6H, -CO-C(CH3)2), 0.95 (s, 3H, -CH3), 0.92 (m, 6H, 2 × -CH3), 0.89 (s, 3H, 2 × -CH3), 0.82
(s, 6H, 2 × -CH3), 0.79 (s, 3H, -CH3). Calcd for C51H84N2O8Na (M+Na)+: 875.6125.
Found: 875.6118.
Dimethyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-9-
aminononanoyl]-L-glutamate (13)—Yield 12 mg (64%). 1H NMR δ 6.57 (d, J = 7.8
Hz, -CONH-), 5.78 (bs, 1H, -CONH-), 4.72 and 4.59 (2s, 1H each, =CH2), 4.61–4.66 (m,
1H, -CO-CH-NH-), 4.61 (t, J = 6.6 Hz, 1H, -CH- in 3), 3.76 and 3.69 (2s, 3H each, 2 × -
OCH3), 3.12–3.32 (m, 2H, -CONH-CH2-), 3.03–3.09 (m, 1H, -CH- in 19), 2.67 and 2.57
(2d, J = 15.9 Hz, 1H each, -C(CH3)2-CH2-), 2.15–2.48 (m, 7H, 2 × –COCH2-, -NHCH-
CH2-, -CH- in 13), 1.68 (s, 3H, -CH3 in 30), 1.28 (m, 6H, -CO-C(CH3)2), 0.95 (s, 3H, -
CH3), 0.91 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.79 (s, 3H, -CH3). Calcd for
C52H84N2O10Na (M+Na)+: 919.6024. Found: 919.6052.
Methyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-9-
aminononanoyl]-L-alaninate (14)—Yield 7 mg (42%). 1H NMR δ 6.33 (d, J = 6.3 Hz, -
CONH-CH-), 5.76 (bs, 1H, -CONH-), 4.73 (s, 1H, =CH), 4.53–4.63 (m, 2H, =CH, -CO-CH-
NH-), 4.48 (t, J = 8.4 Hz, 1H, -CH- in 3), 3.77 (s, 3H, -OCH3), 3.15–3.30 (m, 2H, -CONH-
CH2-), 3.07 (t, 1H, J = 8.4 Hz, 1H, -CH- in 19), 2.68 and 2.57 (2d, J = 15.6 Hz, 1H each, -
C(CH3)2-CH2-), 2.38 (t, J = 10.8 Hz, 1H, -CH- in 13), 2.27 (t, J = 7.2 Hz, 2H, -COCH2-)
1.68 (s, 3H, -CH3 in 30), 1.43 and 1.41 (d, J = 7.5 Hz, 3H, -CH-CH3), 1.30 (m, 6H, -CO-
C(CH3)2), 0.96 (s, 3H, -CH3), 0.91 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.80 (s, 3H, -
CH3). Calcd for C49H80N2O8Na (M+Na)+: 847.5812. Found: 847.5813.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-9-aminononanoyl]-
aminoacetonitrile (15)—Yield 12 mg (46%). 1H NMR δ 6.57 and 5.66 (2bs, 1H each, 2
× -CONH-), 4.72 and 4.59 (2s, 1H each, =CH2), 4.48 (t, 1H, J = 6.0 Hz, -CH- in 3), 4.18 (d,
J = 5.7 Hz, 2H, -CH2-CN), 3.08–3.34 (m, 3H, -CONH-CH2-, -CH- in 19), 2.67 and 2.55 (2d,
J = 15.9 Hz, 2H, -C(CH3)2-CH2-), 2.42 (t, J = 11.4 Hz, 1H, -CH- in 13), 2.25 (t, J = 7.5 Hz,
2H, -CO-CH2-), 1.68 (s, 3H, -CH3 in 30), 1.29 (m, 6H, -CO-C(CH3)2), 0.96 (s, 3H, -CH3),
0.92 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.80 (s, 3H, -CH3). Calcd for C47H75N3O6Na (M
+Na)+: 800.5554. Found: 800.5535.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-9-aminononanoyl]-
aminopropionitrile (16)—Yield 11 mg (46%). 1H NMR δ 6.40 (bs, 1H, -CONH-), 5.73
(t, J = 5.1 Hz, 1H, -CONH-), 4.71 and 4.59 (2s, 1H each, =CH2), 4.48 (t, 1H, J = 6.9 Hz, -
CH- in 3), 3.52 (dd, J = 6.0 Hz, J = 15.6 Hz, 2H, -CONH-CH2-), 3.14–3.30 (m, 2H, -CONH-
CH2-), 3.07 (dt, J = 3.6 Hz, J = 14.7 Hz, 1H, -CH- in 19), 2.53–2.70 (m, 4H, -C(CH3)2-
CH2-, -CH2-CN), 2.39 (t, J = 11.7 Hz, 1H, -CH- in 13), 2.24 (t, J = 8.1 Hz, 2H, -CO-CH2-),
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1.68 (s, 3H, -CH3 in 30), 1.29 (m, 6H, -CO-C(CH3)2), 0.95 (s, 3H, -CH3), 0.91 (s, 3H, -
CH3), 0.82 (s, 6H, 2 × -CH3), 0.79 (s, 3H, -CH3). Calcd for C48H77N3O6Na (M+Na)+:
814.5710. Found: 814.5719.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-9-aminononanoyl]-
N-methylaminoacetonitrile (17)—Yield 7 mg (39%). 1H NMR δ 5.75 (bs, 1H, -
CONH-), 4.72 and 4.59 (2s, 1H each, =CH2), 4.46 (t, 1H, J = 6.6 Hz, -CH- in 3), 4.37 (s,
2H, -CH2-CN), 3.04–3.28 (m, 6H, -CONH-CH2-, -N-CH3, -CH- in 19), 2.67 and 2.55 (2d, J
= 15.9 Hz, 2H each, -C(CH3)2-CH2-), 2.34–2.39 (m, 3H, -NCO-CH2-, -CH- in 13), 1.67 (s,
3H, -CH3 in 30), 1.28 (m, 6H, -COC(CH3)2), 0.95 (s, 3H, -CH3), 0.91 (s, 3H, -CH3), 0.82 (s,
6H, 2 × -CH3), 0.79 (s, 3H, -CH3). Calcd for C48H78N3O6 (M+H)+: 792.5891. Found:
792.5923.
Methyl N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-oyl]-10-
aminodecanoyl]-L-glutaminate (18)—Yield 6 mg (34%). 1H NMR δ 7.16 and 6.91
(2bs, 1H each, -CONH2-) 6.56 (d, J = 6.9 Hz, 1H, -CONH-), 5.71 (bs, 1H, -CONH-), 4.72
(1s, 1H each, =CH), 4.59 (m, 2H, -CONH-CH-, =CH), 4.48 (m, 1H, -CH- in 3), 3.77 (s, 3H,
-OCH3-), 3.33–3.42 and 3.02–3.34 (m, 3H, -CO-CH2-, -CH- in 19), 2.71 and 2.55 (2d, J =
15.6 Hz, 1H each, -C(CH3)2-CH2-), 1.68 (s, 3H, -CH3 in 30), 1.29 (m, 6H, -CO-C(CH3)2),
0.96 (s, 3H, -CH3), 0.91 (s, 3H, -CH3), 0.82 (s, 3H, -CH3), 0.80 (s, 3H, -CH3), 0.79 (s, 3H, -
CH ). Calcd for C52H85N3O9Na (M+Na)+: 918.6183. Found: 918.6173.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-7-aminoheptyl]-Na-
boc-L-glutaminamide (19)—Yield 9 mg (32%). 1H NMR δ 6.96 (d, J = 15.3 Hz, 1H, -
CONH-), 6.73 (bs, 1H, -CONH-), 6.06 (bs, 2H, -CONH2), 5.71–5.81 (m, 1H, -CONH-),
4.72 and 4.59 (2s, 1H each, =CH2), 4.45 (t, 1H, J = 8.4 Hz, -CH- in 3), 4.10–4.23 (m, 1H, -
COCH-), 3.03–3.35 (m, 5H, 2 × -CONH-CH2-, -CH- in 19), 2.69 and 2.54 (2d, J = 15.9 Hz,
1H each, -C(CH3)2-CH2-), 2.32–2.39 (m, 3H, -CH2-CONH2, -CH- in 13), 1.67 (s, 3H, -CH3
in 30), 1.43 (s, 9H, -C(CH3)3), 1.29 (m, 6H, -CO-C(CH3)2), 0.95 (s, 3H, -CH3), 0.91 (s, 3H,
-CH3), 0.81 (s, 6H, 2 × -CH3), 0.78 (s, 3H, -CH3). Calcd for C53H89N4O9 (M+H)+:
925.6630. Found: 925.6591.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-7-aminoheptyl]-Na-
boc-L-alaninamide (20)—Yield 6 mg (23%). 1H NMR δ 6.53 (t, J = 4.8 Hz, 1H, -
CONH-), 5.77 (t, J = 5.4 Hz, 1H, -CONH-), 5.30 (bs, 1H, -CONH-), 4.72 and 4.59 (2s, 1H
each, =CH2), 4.68 (t, 1H, J = 6.9 Hz, -CH- in 3), 4.16–4.23 (m, 1H, -COCH-), 3.03–3.28 (m,
5H, 2 × -CONH-CH2-, -CH- in 19), 2.67 and 2.56 (2d, J = 16.2 Hz, 1H each, -C(CH3)2-
CH2-), 2.38 (t, J = 12.0 Hz, 1H, -CH- in 13), 1.67 (s, 3H, -CH3 in 30), 1.44 (s, 9H, -
C(CH3)3), 1.35 (d, J = 6.9 Hz, 3H, -CH-CH3), 1.28 (m, 6H, -CO-C(CH3)2), 0.95 (s, 3H, -
CH3), 0.90 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.79 (s, 3H, -CH3). Calcd for C51H86N3O8
(M+H)+: 868.6415. Found: 868.6462.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-8-aminooctyl]-Na-
boc-L-glutaminamide (21)—Yield 8 mg (35%). 1H NMR δ 7.17, 6.86, 6.60, 5.73 and
(4bs, 1H each, 3 × -CONH-, 1 H in -CONH2-), 4.72 and 4.59 (2s, 1H each, =CH2), 4.47 (t,
1H, J = 6.6 Hz, -CH- in 3), 4.13 (m, 1H, -COCH-), 3.34–3.42 (m, 1H, 1H in -CONH-CH2-),
3.23 (dd, J = 6.3 Hz, J = 13.8 Hz, 2H, -CONH-CH2-), 3.02–3.12 (m, 2H, 1H in -CONH-
CH2-, -CH- in 19), 2.71 and 2.54 (2d, J = 15.6 Hz, 1H each, -C(CH3)2-CH2-), 1.68 (s, 3H, -
CH3 in 30), 1.43 (s, 9H, -C(CH3)3), 1.28 (m, 6H, -CO-C(CH3)2), 0.96 (s, 3H, -CH3), 0.91 (s,
3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.79 (s, 3H, -CH3). Calcd for C54H90N4O9Na (M+Na)+:
961.6605. Found: 961.6623.
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boc-L-valinamide (22)—Yield 11 mg (41%). 1H NMR δ 6.45 (bs, 1H, -CONH-), 5.74 (t,
J = 5.7 Hz, 1H, -CONH-), 5.40 (bs, 1H, -CONH-), 4.72 and 4.58 (2s, 1H each, =CH2), 4.47
(t, 1H, J = 7.2 Hz, -CH- in 3), 3.84 (t, J = 7.8 Hz, 1H, -COCH-), 3.06–3.29 (m, 6H, 2 × -
CONH-CH2-, -CH-(CH3)2, -CH- in 19), 2.67 and 2.56 (2d, J = 15.9 Hz, 1H each, -C(CH3)2-
CH2-), 2.38 (t, J = 9.9 Hz, 1H, -CH- in 13), 1.67 (s, 3H, -CH3 in 30), 1.43 (s, 9H, -C(CH3)3),
1.35 (d, J = 6.9 Hz, 3H, -CH-CH3), 1.28 (m, 12H, -CH-(CH3)2, -CO-C(CH3)2), 0.95 (s, 3H,
-CH3), 0.91 (s, 3H, -CH3), 0.81 (s, 6H, 2 × -CH3), 0.79 (s, 3H, -CH3). Calcd for
C54H91N3O8Na (M+Na)+: 932.6704. Found: 932.6708.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-8-aminooctyl]-Na-
boc-L-alaninamide (23)—Yield 3 mg (17%). 1H NMR δ 6.36 (bs, 1H, -CONH-), 5.71 (t,
J = 5.4 Hz, 1H, -CONH-), 5.18 (bs, 1H, -CONH-), 4.72 and 4.59 (2s, 1H each, =CH2), 4.48
(t, 1H, J = 6.3 Hz, -CH- in 3), 4.16–4.25 (m, 1H, -COCH-), 3.06–3.30 (m, 5H, 2 × -CONH-
CH2-, -CH- in 19), 2.67 and 2.56 (2d, J = 15.9 Hz, 1H each, -C(CH3)2-CH2-), 1.68 (s, 3H, -
CH3 in 30), 1.44 (s, 9H, -C(CH3)3), 1.35 (d, J = 7.2 Hz, 3H, -CH-CH3), 1.29 (m, 6H, -CO-
C(CH3)2), 0.95 (s, 3H, -CH3), 0.89 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.80 (s, 3H, -
CH3). Calcd for C52H86N3O8 (M-H)+: 880.6415. Found: 880.6389.
2-(Boc-amino)-4-cyano-N-[N’-[3β-O-(3’,3’-dimethylsuccinyl)-betulinic acid-28-
oyl]-8-aminooctyl]butanamide (24)—Yield 2 mg (22%). 1H NMR δ 6.32 (bs, 1H, -
CONH-), 5.68 (bs, 1H, -CONH-), 5.30 (bs, 1H, -CONH-), 4.72 and 4.59 (2s, 1H each,
=CH2), 4.46 (m, 1H, -CH- in 3), 4.16–4.27 (m, 5H, -CH2-CH2-CN, -COCH-), 3.10–3.30 (m,
5H, 2 × -CONH-CH2-, -CH- in 19), 2.68 and 2.56 (2d, J = 15.0 Hz, 1H each, -C(CH3)2-
CH2-), 1.68 (s, 3H, -CH3 in 30), 1.45 (s, 9H, -C(CH3)3), 1.30 (m, 6H, -CO-C(CH3)2), 0.92
(s, 6H, 2 × -CH3), 0.89 (s, 3H, -CH3), 0.83 (s, 6H, 2 × -CH3), 0.80 (s, 3H, -CH3). Calcd for
C54H87N4O8 (M-H)-: 919.6524. Found: 919.6481.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-8-aminooctyl]-Na-
boc-L-prolinamide (25)—Yield 9 mg (34%). 1H NMR δ 6.90 and 6.48 (2bs, 1H each, 2
× -CONH-), 4.72 and 4.59 (2s, 1H each, =CH2), 4.75 (t, 1H, J = 9.6 Hz, -CH- in 3), 4.22 (t, J
= 4.5 Hz, 1H, -COCH-), 3.06–3.50 (m, 7H, 2 × -CONH-CH2-, -CON-CH2-, -CH- in 19),
2.66 and 2.56 (2d, J = 16.2 Hz, 1H each, -C(CH3)2-CH2-), 2.39 (t, J = 10.8 Hz, 1H, -CH- in
13), 1.68 (s, 3H, -CH3 in 30), 1.45 (s, 9H, -C(CH3)3), 1.25 (s, 6H, -CO-C(CH3)2), 0.95 (s,
3H, -CH3), 0.91 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.80 (s, 3H, -CH3). Calcd for
C54H88N3O8 (M-H)-: 906.6571. Found: 906.6523.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-9-aminononactyl]-
Na-boc-L-glutaminamide (26)—Yield 6 mg (21%). 1H NMR δ 7.10, 6.93 and 6.63 (3s,
1H each, 2 × -CONH-, 1H in -CONH2), 5.75 (t, J = 5.4 Hz, 1H, -CONH-), 5.71 (bs, 1H, 1H
in -CONH2), 4.72 and 4.59 (2s, 1H each, =CH2), 4.48 (dd, 1H, J = 6.0 Hz, J = 9.6 Hz, -CH-
in 3), 4.21 (dd, J = 4.2 Hz, J = 6.0 Hz, 1H, -COCH-), 3.05–3.40 (m, 5H, 2 × -CONH-CH2-, -
CH- in 19), 2.75 and 2.53 (2d, J = 15.9 Hz, 1H each, -C(CH3)2-CH2-), 1.68 (s, 3H, -CH3 in
30), 1.43 (s, 9H, -C(CH3)3), 1.29 and 1.27 (2s, 3H each, -CO-C(CH3)2), 1.11 (s, 3H, -CH3),
0.96 (s, 3H, -CH3), 0.91 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.79 (s, 3H, -CH3). Calcd for
C55H91N4O9 (M-H)-: 951.6786. Found: 951.6762.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-9-aminononactyl]-
Na-boc-L-alaninamide (27)—Yield 12 mg (45%). 1H NMR δ 6.42 and 5.50 (2bs, 1H
each, 2 × -CONH-), 5.70 (t, J = 5.4 Hz, 1H, -CONH-), 4.72 and 4.59 (2s, 1H each, =CH2),
4.47 (dd, 1H, J = 6.0 Hz, J = 9.6 Hz, -CH- in 3), 4.21 (dd, J = 3.3 Hz, J = 6.3 Hz, 1H, -
COCH-), 3.02–3.30 (m, 5H, 2 × -CONH-CH2-, -CH- in 19), 2.67 and 2.55 (2d, J = 15.6 Hz,
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1H each, -C(CH3)2-CH2-), 2.38 (t, J = 6.0 Hz, 1H, -CH- in 13), 1.67 (s, 3H, -CH3 in 30),
1.43 (s, 9H, -C(CH3)3), 1.35 (d, J = 7.2 Hz, 3H, -CHCH3), 1.28 and 1.27 (2s, 3H each, -CO-
C(CH3)2), 0.95 (s, 3H, -CH3), 0.91 (s, 3H, -CH3), 0.82 (s, 6H, 2 × -CH3), 0.79 (s, 3H, -
CH3). Calcd for C53H90N3O8 (M+H)+: 896.6728. Found: 896.6773.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-9-aminononactyl]-
Na-boc-L-glycinamide (28)—Yield 6 mg (34%). 1H NMR δ 6.41, 5.72 and 5.34 (3bs,
1H each, 3 × -CONH-), 4.73 and 4.59 (2s, 1H each, =CH2), 4.46–4.51 (m, 1H, -CH- in 3),
3.80 (d, J = 3.6 Hz, 2H, -COCH2-NH-), 3.02–3.36 (m, 5H, 2 × -CONH-CH2-, -CH- in 19),
2.70 and 2.56 (2d, J = 15.9 Hz, 1H each, -C(CH3)2-CH2-), 1.68 (s, 3H, -CH3 in 30), 1.45 (s,
9H, -C(CH3)3), 1.25 (m, 6H, -COC(CH3)2), 0.96 (s, 3H, -CH3), 0.92 (s, 3H, -CH3), 0.82 (s,
6H, 2 × -CH3), 0.80 (s, 3H, -CH3). Calcd for C52H88N3O8 (M+H)+: 882.6571. Found:
882.6553.
N-[N’-[3β-O-(3’,3’-Dimethylsuccinyl)-betulinic acid-28-oyl]-9-aminononactyl]-
Na-boc-L-asparaginamide (29)—Yield 8 mg (41%). 1H NMR δ 6.72, 6.21, 6.13 and
5.69 (4bs, 1H each, 3 × -CONH-, 1H in -CO-NH2), 4.73 and 4.59 (2s, 1H each, =CH2),
4.42–4.50 (m, 2H, -COCH-, -CH- in 3), 3.64–3.24 and 2.84–3.20 (m, 7H, 2 × -CONH-CH2-,
-COCH2-, -CH- in 19), 2.78 and 2.47 (2d, J = 15.0 Hz, 1H each, -C(CH3)2-CH2-), 1.68 (s,
3H, -CH3 in 30), 1.46 (s, 9H, -C(CH3)3), 1.25 (m, 6H, -CO-C(CH3)2), 0.96 (s, 3H, -CH3),
0.92 (s, 3H, -CH3), 0.82 (s, 3H, -CH3), 0.81 (s, 3H, -CH3), 0.75 (s, 3H, -CH ). Calcd for
C54H89N4O9 (M-H)-: 937.6630. Found: 937.6595.
Construction of BVM-R Variants
Construction of these mutants was achieved by using a QuickChange site-directed
mutagenesis kit purchased from Stratagene as previously described.23 The plasmid, pNL4-3,
was used as a template to create all the mutants listed in Table 1. Each mutation was
introduced into pNL4-3 following the protocol provided by Stratagene.
Multi-Cycle Viral Replication in MT4 Cell Assay
HIV-1 NL4-3 or the resistant variants with a multiplicity of infection (MOI) of 0.001
TCID50/cell was used to infect MT4 cells in the presence of compounds at various
concentrations. On day 4 post-infection, supernatant samples were harvested and assayed for
p24 using an ELISA kit from Perkin Elmer. The antiviral potency is defined as the drug
concentration that reduces the amount of p24 by 50% (IC50).
Cytotoxicity Assay
A CytoTox-Glo™ cytotoxicity assay (Promega) was used to determine the cytotoxicity of
the synthesized BA derivatives. MT4 cells were cultured in the presence of various
concentrations of the compounds for 4 days. Percent of viable cells was determined by
following the protocol provided by the manufacturer. The 50% cytotoxic concentration
(CC50) was defined as the concentration that caused a 50% reduction of cell viability.
Determination of Anti-HIV-1 Maturation Activity
Analysis of anti-maturation activity was performed as described previously.10,18 Briefly,
293T cells were transfected with plasmids with corresponding proviruses, such as pNL4-3.
The culture supernatant was harvested for Western blot analysis two days after transfection.
The signature event of anti-maturation activity of compound 1 is a partial inhibition of CA-
SP1 (p25) cleavage that occurs without interfering with other Gag cleavage sites. Inhibition
of CA-SP1 cleavage resulted in an accumulation of p25. Accumulation of CA-SP1 (p25)
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was analyzed with a Western blot analysis using a monoclonal antibody produced by the
HIV-1 p24 hybridoma, 183-H12-5C (NIH AIDS Reagent Program).
Fusion Assay
The fusion assay used in this study was described previously.24 The fusion assay was
performed by transfecting monkey kidney cells (COS) with the expression vector pars that
contained HIV-1 Env and tat genes. COS cells (1 × 106 cells/mL) were mixed with 5 µg of
the Env-expressing vector and incubated on ice for 10 minutes. Electroporation was
performed using a gene pulsar (Bio-Rad, Hercules, CA) with capacitance set at 950 F and
voltage at 150 V. The transfected COS cells were cultured for one day and then mixed with
TZM-bl cells. TZM-bl cells were incubated with the Env-expressing COS cells in the
presence of inhibitors in 96-well flat-bottom plates (Costar) overnight. Fusion was measured
by quantifying luciferase activity in the fused cells using a Bright-Glow luciferase assay kit
(Promega, Luis Obispo, CA). Inhibition of the Env-mediated membrane fusion was
expressed as a percentage of the control (Env-mediated membrane fusion in the absence of
inhibitors).
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Structure of compound 1 analogs.
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Synthesis of Compounds 2-18a
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Synthesis of Compounds 19-29a
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Inhibition of CA-SP1 processing. The anti-maturation activity of 1 and 6 was determined by
transfecting 293T cells with the following plasmids: (a) pNL4-3 or pNL4-3/V370A; (b)
pNL4-3/V362I. The viruses produced in the presence of the compounds were collected two
days after transfection.
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Compound 6 did not inhibit HIV-1 Env–mediated cell-cell fusion. COS cells (1 × 106 cells/
mL) were transfected by electroporation with HIV-1 NL4-3 Env-expressing vector (2 μg)
for one day before mixing with TZM-bl cells for fusion. The luciferase expression measured
as relative luciferase units (RLU) in the fusion cells was quantified 24 hours after cell
mixing.24 HIV-1 Env-mediated cell-cell fusion in the absence of compounds is defined as
100% control. Each data point in the figure represents mean +/- SD of three tests.
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Table 1
Genotypes of NL4-3 Variants Carrying BVM-R Polymorphisms
Virus (Gag) CA SP1
362 369 371
NL4-3 V L A E A M S Q V T N S A
NL4-3/V370Δ V L A E A M S Q Δ T N S A
NL4-3/V370A V L A E A M S Q A T N S A
NL4-3/T371Δ V L A E A M S Q V Δ N S A
NL4-3/V362I V I A E A M S Q V T N S A
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Table 4




Compound 1 Compound 6
NL4-3 0.076 ± 0.019 0.008 ± 0.0017
NL4-3/V370Δ > 6.8 0.32 ± 0.077
NL4-3/V370Δ > 6.8 0. 158 ± 0.048
NL4-3/T371Δ > 6.8 0.067 ± 0.012
NL4-3/V362I > 6.8 0.016±0.0042
a
IC50: the numbers in the table are mean +/- SD from three independent experiments.
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